These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25468710)

  • 21. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.
    Abdel-Fatah TM; Russell R; Albarakati N; Maloney DJ; Dorjsuren D; Rueda OM; Moseley P; Mohan V; Sun H; Abbotts R; Mukherjee A; Agarwal D; Illuzzi JL; Jadhav A; Simeonov A; Ball G; Chan S; Caldas C; Ellis IO; Wilson DM; Madhusudan S
    Mol Oncol; 2014 Oct; 8(7):1326-38. PubMed ID: 24880630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
    Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
    Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
    Tilli TM; Carels N; Tuszynski JA; Pasdar M
    Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
    Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
    Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.
    Mohni KN; Kavanaugh GM; Cortez D
    Cancer Res; 2014 May; 74(10):2835-45. PubMed ID: 24662920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
    Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
    Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
    Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
    Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-195 suppresses non-small cell lung cancer by targeting CHEK1.
    Liu B; Qu J; Xu F; Guo Y; Wang Y; Yu H; Qian B
    Oncotarget; 2015 Apr; 6(11):9445-56. PubMed ID: 25840419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of a novel ataxia-telangiectasia mutated and Rad3 related/checkpoint kinase 1-dependent prometaphase checkpoint in cancer cells by diallyl trisulfide, a promising cancer chemopreventive constituent of processed garlic.
    Herman-Antosiewicz A; Stan SD; Hahm ER; Xiao D; Singh SV
    Mol Cancer Ther; 2007 Apr; 6(4):1249-61. PubMed ID: 17406033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHEK1 coordinates DNA damage signaling and meiotic progression in the male germline of mice.
    Abe H; Alavattam KG; Kato Y; Castrillon DH; Pang Q; Andreassen PR; Namekawa SH
    Hum Mol Genet; 2018 Apr; 27(7):1136-1149. PubMed ID: 29360988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATR inhibition preferentially targets homologous recombination-deficient tumor cells.
    Krajewska M; Fehrmann RS; Schoonen PM; Labib S; de Vries EG; Franke L; van Vugt MA
    Oncogene; 2015 Jun; 34(26):3474-81. PubMed ID: 25174396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Biskup E; Naym DG; Gniadecki R
    J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
    Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
    Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.
    Brooks DL; Schwab LP; Krutilina R; Parke DN; Sethuraman A; Hoogewijs D; Schörg A; Gotwald L; Fan M; Wenger RH; Seagroves TN
    Mol Cancer; 2016 Mar; 15():26. PubMed ID: 27001172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/β-catenin/EMT signalling axis.
    Sun L; Shi C; Liu S; Zhang E; Yan L; Ji C; Zhao Y
    Gene; 2020 Jul; 747():144657. PubMed ID: 32298762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of pharmacodynamic biomarkers for ATR inhibitors.
    Chen T; Middleton FK; Falcon S; Reaper PM; Pollard JR; Curtin NJ
    Mol Oncol; 2015 Feb; 9(2):463-72. PubMed ID: 25459351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance.
    Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
    Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.